Hindalco, AluChem Scrap Specialty Alumina Deal on Extended Delays
Hindalco and AluChem scrap specialty alumina deal with no penalty. HDFC Bank CEO, DLF sell-out, Ola pledge, Gland Pharma deal also in focus.
Hindalco Industries and US-based AluChem Companies have terminated their equity purchase agreement to acquire AluChem’s specialty alumina business, the companies said in a statement. The breakup follows extended closing delays that both sides said were beyond their control.
Hindalco said its overarching strategy of scaling high-value, technology-led value-added products in its speciality alumina segment remains unaffected by this decision. The mutually agreed cancellation carries no break fee or litigation, the company added. Hindalco did not disclose the original deal value or the specific causes of the delay beyond factors outside either party’s control.
Specialty alumina commands higher margins than standard smelter-grade alumina and is used in applications such as refractory materials, medical implants, and electronics. Hindalco had flagged the acquisition as a way to deepen its presence in that market and reduce reliance on commodity-grade volumes. With the deal off, the company may now pursue an alternative acquisition or pivot back to organic capacity expansion in specialty grades. Hindalco gave no timeline for a replacement deal.
Elsewhere in Indian corporate news, HDFC Bank received RBI approval to appoint Anup Bagchi as Managing Director and CEO for a three-year term. Bagchi brings over three decades of experience across banking, capital markets, and insurance. The stock carries an Alpha Score of 39/100 (Mixed) on AlphaScala. ICICI Life Insurance named Sidharatha Mishra as its new MD and CEO, subject to regulatory clearance. ICICI Bank, with an Alpha Score of 57/100 (Moderate), also featured in the day’s filings.
DLF sold out its luxury retirement community The Aureva in Gurugram for about ₹1,985 crore, underscoring strong demand in the segment. Ola Electric clarified that promoter Bhavish Aggarwal pledged a 4.32% stake solely to raise capital for the company’s upcoming rights issue. Gland Pharma approved a $21 million investment to acquire a 60% stake in Novelstar Pharma via its US subsidiary. Shyam Metalics signed a non-binding MoU with the Maharashtra government to set up a ₹50,000 crore steel complex in Chandrapur.
Aurobindo Pharma received USFDA approval to market generic Perampanel tablets, a bioequivalent to Catalyst Pharmaceuticals’ Fycompa. The product will be manufactured at its APL Healthcare unit and launched in Q3-FY27. Sudarshan Chemicals faced search proceedings by Maharashtra GST officials but said the action has no material impact on financials or operations. Rail Vikas Nigam said East Coast Railway cancelled a letter of acceptance for a video surveillance project by mutual consent, with no financial repercussions.
The Hindalco deal termination is contained: no penalty, no litigation, and a clear mutual statement. The market’s attention now turns to whether Hindalco will announce an alternative path into specialty alumina in the coming quarters. The company gave no timeline for a replacement deal.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.